Search results
FDA grants Medivir´s MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the...
FOX 4 Kansas City· 3 days agoThe FDA defines a rare pediatric disease as a serious or life-threatening disease in which the...
Vertex has top orphan drug in the pipeline, as pharma eyes shiny obesity drugs: report
FierceBiotech· 4 days agoVertex’s cystic fibrosis triple combo is poised to become the top selling orphan drug in terms of...
Caliway Announced CBL-514 Phase 2 Study for Cellulite Treatment Met All Primary and Secondary...
WCMH Columbus· 3 days agoCBL-514 is under development for multiple indications, including Cellulite, Local Fat Reduction (currently in Phase 2b), and Durum's disease (currently in Phase 2), which brought Caliway the ...
Malaria is still killing people in Kenya, but a vaccine and local drug production may help
WDTN-TV 2 Dayton· 3 days agoMIGORI, Kenya (AP) — As the coffin bearing the body of Rosebella Awuor was lowered into the grave,...
Medicure Receives US FDA Fast Track Designation for MC-1 for PNPO Deficiency
Morningstar· 5 days agoFood and Drug Administration (FDA) has granted Fast Track designation for MC-1, an investigational product for the prevention or treatment of seizures associated with pyridox ...
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q1 2024 Earnings Call Transcript
Seeking Alpha· 3 days agoSwedish Orphan Biovitrum AB (publ) (OTCPK:BIOVF) Q1 2024 Earnings Conference Call April 25, 2024 10:00 AM ETCompany ParticipantsGuido Oelkers - Chief...
Sobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly...
CW39 NewsFix· 2 days agoSobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of efanesoctocog alfa, for ...
ASCO 2024 | Ascentage Pharma to Present Four Studies, Including an Oral Report Featuring the Latest...
Morningstar· 4 days agoSUZHOU, China and ROCKVILLE, Md., April 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis ...
Lisata Therapeutics advances lead asset LSTA1 for treatment of advanced solid tumors
Proactive Investors· 5 days agoLisata Therapeutics Inc (NASDAQ:LSTA) CEO David J. Mazzo discusses the oncology company's focus and...
Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study
Zacks via Yahoo Finance· 5 days agoSanofi's (SNY) BTK inhibitor, rilzabrutinib, demonstrates durable platelet response in the phase III...